Association of Computed Tomography Radiomics Signature with Progression-free Survival in Neuroblastoma Patients

被引:2
|
作者
Wang, H. [1 ]
Li, T. [1 ]
Xie, M. [1 ]
Si, J. [1 ]
Qin, J. [1 ]
Yang, Y. [1 ]
Zhang, L. [1 ]
Ding, H. [1 ]
Chen, X. [1 ]
He, L. [1 ]
机构
[1] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Childrens Hosp,Key Lab Child Dev & Disorders, Minist Educ,Chongqing Key Lab Pediat,Dept Neurol, 136 Zhongshan Rd 2, Chongqing 400014, Peoples R China
关键词
Computed tomography; neuroblastoma; prognosis; progression-free survival; radiomics; PATHOLOGY CLASSIFICATION; PROGNOSTIC VALUE;
D O I
10.1016/j.clon.2023.06.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To investigate the association of computed tomography radiomics signature with progression-free survival (PFS) in neuroblastoma patients. Materials and methods: We retrospectively included 167 neuroblastoma patients who were divided into a training set and a test set through stratified sampling at a ratio of 7:3. Regions of interest of the primary tumours were delineated on pretreatment contrast-enhanced computed tomography images and radiomics features were extracted from them. The intraclass correlation coefficient, Pearson correlation coefficient, and least absolute shrinkage and selection operator Cox regression algorithm were applied to select radiomics features and construct the radiomics signature. The effectiveness of the signature in predicting PFS was evaluated using the concordance index (C-index) and 95% confidence interval in both the training and the test sets. The time-dependent receiver operator characteristic curve of the radiomics signature was plotted and the area under the curve (AUC) was calculated. A calibration curve was used to assess the difference between the predicted probability of the radiomics signature and the observed probability at different time points. Results: The radiomics signature was composed of six features, which achieved a C-index of 0.733 (95% confidence interval 0.664-0.803) in the training set and 0.734 (95% confidence interval 0.608-0.861) in the test set. In the training set, the radiomics signature yielded an AUC of 0.707, 0.737, 0.788, 0.859 and 0.829 for 1-, 2-, 3-, 4- and 5-year PFS, respectively. Similarly, the radiomics signature exhibited an AUC of 0.738, 0.807, 0.761, 0.787 and 0.818 for 1-, 2-, 3-, 4- and 5-year PFS, respectively, in the test set. The calibration curves showed no significant difference between the predicted probability of the radiomics signature and the observed probability for up to 5 years. Conclusions: Computed tomography radiomics features exhibit a significant correlation with the PFS of neuroblastoma patients, particularly in terms of longterm outcomes. (c) 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:e639 / e647
页数:9
相关论文
共 50 条
  • [21] Association between progression-free survival and patients' quality of life in cancer clinical trials
    Hwang, Thomas J.
    Gyawali, Bishal
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (07) : 1746 - 1751
  • [22] Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma
    Mahajan, Ujjwal Mukund
    Langhoff, Eno
    Goni, Elisabetta
    Costello, Eithne
    Greenhalf, William
    Halloran, Christopher
    Ormanns, Steffen
    Kruger, Stephan
    Boeck, Stefan
    Ribback, Silvia
    Beyer, Georg
    Dombroswki, Frank
    Weiss, Frank-Ulrich
    Neoptolemos, John P.
    Werner, Jens
    D'Haese, Jan G.
    Bazhin, Alexandr
    Peterhansl, Julian
    Pichlmeier, Svenja
    Buechler, Markus W.
    Kleeff, Joerg
    Ganeh, Paula
    Sendler, Matthias
    Palmer, Daniel H.
    Kohlmann, Thomas
    Rad, Roland
    Regel, Ivonne
    Lerch, Markus M.
    Mayerle, Julia
    GASTROENTEROLOGY, 2018, 155 (05) : 1625 - +
  • [23] A tumor and immune related miRNA signature predicts progression-free survival of melanoma patients treated with ipilimumab
    Tarhini, Ahmad
    Vallabhaneni, Priyanka
    Floros, Theofanis
    LaFramboise, William A.
    Benos, Panayiotis V.
    dos Santos, Lucas Santana
    CANCER RESEARCH, 2016, 76
  • [24] CT-based radiomics signature analysis for sevaluation of response to induction chemotherapy and progression-free survival in locally advanced hypopharyngeal carcinoma
    Liu, Xiaobin
    Long, Miaomiao
    Sun, Chuanqi
    Yang, Yining
    Lin, Peng
    Shen, Zhiwei
    Xia, Shuang
    Shen, Wen
    EUROPEAN RADIOLOGY, 2022, 32 (11) : 7755 - 7766
  • [25] CT-based radiomics signature analysis for evaluation of response to induction chemotherapy and progression-free survival in locally advanced hypopharyngeal carcinoma
    Xiaobin Liu
    Miaomiao Long
    Chuanqi Sun
    Yining Yang
    Peng Lin
    Zhiwei Shen
    Shuang Xia
    Wen Shen
    European Radiology, 2022, 32 : 7755 - 7766
  • [26] Impact of positron emission tomography- computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation
    Eyre, Toby A.
    Barrington, Sally F.
    Okosun, Jessica
    Abamba, Clementina
    Pearce, Rachel M.
    Lee, Julia
    Carpenter, Ben
    Crawley, Charles R.
    Bloor, Adrian J. C.
    Gilleece, Maria
    Nicholson, Emma
    Shah, Nimish
    Orchard, Kim
    Malladi, Ram
    Townsend, William M.
    HAEMATOLOGICA, 2023, 108 (03) : 785 - 796
  • [27] Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients
    Flanagan, J. M.
    Wilhelm-Benartzi, C. S.
    Metcalf, M.
    Kaye, S. B.
    Brown, R.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2813 - 2818
  • [28] Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer
    Ahn, Jinwoo
    Ahn, Dong-Won
    Park, Jaewoo
    Jung, Kwangrok
    Lee, Jong-Chan
    Hwang, Jin-Hyeok
    Jeong, Ji Bong
    Kim, Jaihwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1981 - 1988
  • [29] THE ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ONCOLOGY TRIALS: A SIMULATION EXERCISE
    Wu, D. B. C.
    Manjula, I. S.
    Yu, D.
    VALUE IN HEALTH, 2022, 25 (01) : S198 - S198
  • [30] MRI radiomics predicts progression-free survival in prostate cancer (vol 12, 974257, 2023)
    Jia, Yushan
    Quan, Shuai
    Ren, Jialiang
    Wu, Hui
    Liu, Aishi
    Gao, Yang
    Hao, Fene
    Yang, Zhenxing
    Zhang, Tong
    Hu, He
    FRONTIERS IN ONCOLOGY, 2023, 12